Michael Casey, MD
Nephrology · Raleigh, NCNPI 1003894056
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,006 of the $6,698 with a category attached, or 74.7%. 26 manufacturers reported payments, led by Roche Products Limited at 37.0% of the total. Reporting peaked in 2023 at $3,112 and has fallen 77.4% since, to $702 in 2025.
Across 162 payments — averaging $41.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$2K
- Amgen$930
- AstraZeneca$593
- Fresenius USA Marketing, Inc.$395
- Otsuka America Pharmaceutical, Inc.$392
- GSK$378
- plus $2K from 20 others
Across 192 payments — averaging $2883.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$324K
- Alnylam Pharmaceuticals Inc.$78K
- Akebia Therapeutics Inc$65K
- Travere Therapeutics, Inc.$45K
- Hoffmann-la Roche Limited$28K
- Astrazeneca UK Limited$13K
What the payments were for
- Travel & lodging$1,62024%
- Food & beverage$5,00675%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 3 | $2,480 |
| Amgen(2 entities) | 34 | $930 |
| AstraZeneca(2 entities) | 20 | $593 |
| Fresenius USA Marketing, Inc. | 16 | $395 |
| Otsuka America Pharmaceutical, Inc. | 13 | $392 |
| GSK | 14 | $378 |
| Akebia Therapeutics Inc | 10 | $312 |
| Aurinia Pharma U.S., Inc. | 6 | $206 |
| Novo Nordisk | 4 | $161 |
| Calliditas Therapeutics US Inc. | 4 | $137 |
| Vifor Pharma, Inc. | 6 | $128 |
| Bayer | 6 | $114 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Novartis | 4 | $62 |
| Apellis Pharmaceuticals, Inc. | 3 | $49 |
| Sanofi | 3 | $41 |
| Lilly USA, LLC | 2 | $39 |
| Nuwellis, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Ardelyx, Inc. | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,698 in reported general payments places this provider in the 85th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 181 | $126,944 |
| LupkynisVoclosporin | 12 | $119,900 |
| VelphoroSucroferric Oxyhydroxide | 34 | $91,062 |
| JardianceEmpagliflozin | 92 | $64,517 |
| InvokanaCanagliflozin | 27 | $32,383 |
| EliquisApixaban | 44 | $21,155 |
| TrulicityDulaglutide | 12 | $12,074 |
| Torsemide | 209 | $4,287 |
| JanuviaSitagliptin Phosphate | 14 | $3,598 |
| Bumetanide | 60 | $2,664 |
| Calcium Acetate | 35 | $2,663 |
| Metoprolol Succinate | 204 | $2,401 |
| Losartan Potassium | 235 | $2,347 |
| Allopurinol | 215 | $2,200 |
| Eplerenone | 20 | $1,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $593 | $126,944181 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $206 | $119,90012 claims |
| Fresenius USA Marketing, Inc.Velphoro | $395 | $91,06234 claims |
| Lilly USA, LLCTrulicity | $39 | $12,07412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Raleigh
- Sammy MoghaziRaleigh$56K
- Jeffrey HoggardRaleigh$48K
- Libbie McKenzieRaleigh$34K
- Karn GuptaRaleigh$10K
- Phillip TimmonsRaleigh$6K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.